PVLA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
22.7M
+6.2%
21.4M
+44.1%
14.9M
+31.4%
11.3M
+11.1%
10.2M
R&D
10.8M
-13.2%
12.5M
+33.6%
9.3M
+31.1%
7.1M
+9.1%
6.5M
SG&A
11.9M
+33.3%
8.9M
+61.8%
5.5M
+32.0%
4.2M
+14.6%
3.6M
Operating Income
-22726000
-6.2%
-21405000
-44.1%
-14855000
-31.4%
-11304000
-11.1%
-10177000
EBITDA
-22726000
-6.2%
-21405000
-44.1%
-14855000
-31.4%
-11304000
-11.1%
-10177000
Net Income
-24643000
-12.7%
-21870000
-38.7%
-15767000
-24.0%
-12714000
-12.1%
-11345000
EPS (Basic)
$-1.70
-11.8%
$-1.52
-26.7%
$-1.20
-12.1%
$-1.07
-3.9%
$-1.03
EPS (Diluted)
$-1.70
-11.8%
$-1.52
-26.7%
$-1.20
-12.1%
$-1.07
-3.9%
$-1.03
Shares (Diluted)
14.5M
+1.2%
14.4M
+9.7%
13.1M
+10.2%
11.9M
+7.3%
11.1M
Palvella Therapeutics (PVLA) — Financials